Adherex Technologies (NASDAQ:FENC) and Biofrontera (NASDAQ:BFRI) Critical Survey

Biofrontera (NASDAQ:BFRI) and Adherex Technologies (NASDAQ:FENC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations and institutional ownership.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Biofrontera and Adherex Technologies, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biofrontera	1	0	1	0	2.00
Adherex Technologies	1	1	4	1	2.71

Adherex Technologies has a consensus price target of $15.40, suggesting a potential upside of 69.23%. Given Adherex Technologies’ stronger consensus rating and higher probable upside, analysts plainly believe Adherex Technologies is more favorable than Biofrontera.

Insider and Institutional Ownership

10.1% of Biofrontera shares are owned by institutional investors. Comparatively, 55.5% of Adherex Technologies shares are owned by institutional investors. 8.1% of Biofrontera shares are owned by insiders. Comparatively, 10.7% of Adherex Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

Biofrontera has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500. Comparatively, Adherex Technologies has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500.

Profitability

This table compares Biofrontera and Adherex Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biofrontera	-25.66%	-515.34%	-53.91%
Adherex Technologies	-17.12%	-43.87%	-11.35%

Valuation & Earnings

This table compares Biofrontera and Adherex Technologies”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biofrontera	$41.71 million	0.31	-$10.54 million	($0.97)	-1.03
Adherex Technologies	$44.64 million	7.11	-$9.74 million	($0.29)	-31.38

Adherex Technologies has higher revenue and earnings than Biofrontera. Adherex Technologies is trading at a lower price-to-earnings ratio than Biofrontera, indicating that it is currently the more affordable of the two stocks.

Summary

Adherex Technologies beats Biofrontera on 14 of the 15 factors compared between the two stocks.

About Biofrontera

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

About Adherex Technologies

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.